Duopharma Biotech Berhad Duopharma Biotech Berhad

Duopharma Biotech Berhad

7148

Rank in Stocks #15495
Duopharma Biotech Berhad, an investment holding firm, is actively engaged in... Duopharma Biotech Berhad, an investment holding firm, is actively engaged in the pharmaceutical sector. Its operations encompass the research, development, manufacturing, distribution, and import of medicinal products, serving markets in Malaysia and internationally. The company's extensive product range includes consumer health items like vitamins, nutritional supplements, pain relievers, eye care solutions, antacids, and skincare products. It also provides generic medications across various therapeutic classes, such as cardiovascular, dermatological, hormonal, respiratory, neurological, musculoskeletal, and anti-infective agents. Furthermore, Duopharma offers specialized pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables, addressing ailments like diabetes, cancer, cardiovascular diseases, and renal disorders. Notable products include vascor, insugen, kytron, and unihepa. Its well-known brands feature Champs, Flavettes, Eye Glo, Proviton, Naturalle, and Uphamol. Beyond its core pharmaceutical activities, the company is also involved in property management and the trading of chemical products. Founded in 1978 and headquartered in Kuala Lumpur, Malaysia, the company adopted its current name, Duopharma Biotech Berhad, in February 2019, having previously been known as CCM Duopharma Biotech Berhad.
Share Price
$0.26961465
Last synced: 2026-11-13
Market Cap
$259.35M
Change (1 day)
0.74%
Change (1 year)
-13.15%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for Duopharma Biotech Berhad (7148)
Operating Margin as of November 2026 TTM: 16.60%
According to Duopharma Biotech Berhad's latest financial reports, its current operating margin (TTM) is 16.60%. At the end of 2025 the company had an operating margin of 15.72%.
Operating Margin history for Duopharma Biotech Berhad from 2006 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 16.60% 5.60%
2025 15.72% 27.08%
2024 12.37% 7.75%
2023 11.48% -13.94%
2022 13.34% -3.96%
2021 13.89% -3.27%
2020 14.36% 6.61%
2019 13.47% 2.90%
2018 13.09% 12.75%
2017 11.61% 10.78%
2016 10.48% -43.66%
2015 18.60% -29.63%
2014 26.43% 6.83%
2013 24.74% -5.97%
2012 26.31% 5.07%
2011 25.04% -5.76%
2010 26.57% -12.97%
2009 30.53% 7.39%
2008 28.43% -19.78%
2007 35.44% 1.66%
2006 34.86% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
19.69% -98.81%
DE
19.68% -98.81%
DE
13.26% -99.20%
JP
17.08% -98.97%
CH
10.53% -99.37%
IL
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Duopharma Biotech Berhad's operating margin

What is Duopharma Biotech Berhad's operating margin?

Duopharma Biotech Berhad's operating margin is 16.60%, as of Nov 2026.

What was Duopharma Biotech Berhad's operating margin in 2025?

In 2025, Duopharma Biotech Berhad's operating margin was 15.72%, compared with 12.37% in 2024.

How has Duopharma Biotech Berhad's operating margin changed since 2020?

From 2020 to 2025, Duopharma Biotech Berhad's operating margin was highest in 2025 (15.72%) and lowest in 2023 (11.48%).

How does Duopharma Biotech Berhad's operating margin compare with similar companies?

Duopharma Biotech Berhad's operating margin (16.60%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with 19.69%.